IKEMEFUNA NKANGINIEME: Open Payments
NPI 1972524049 · CANTON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$412 in 20 payments from 10 companies in 2025. Trend: 2023 $630 · 2024 $479 · 2025 $412
Food & beverage: $412
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $104 |
| Alkermes, Inc. | 3 | $61 |
| ABBVIE INC. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, REXULTI, UZEDY, HETLIOZ, Qelbree, Xelstrym.
Industry payments across OH — which companies pay providers there.
